
|Videos|December 15, 2017
Glasdegib Active in Heavily Pretreated Myelofibrosis
Author(s)Aaron Gerds, MD
This video reviews the phase I portion of a trial testing glasdegib in patients with primary/secondary myelofibrosis previously treated with JAK inhibitors.
Advertisement
In this video, Aaron Gerds, MD, of the Cleveland Clinic in Ohio, discusses the phase I portion of a phase I/II trial testing the smoothened (SMO) inhibitor glasdegib in patients with primary/secondary myelofibrosis previously treated with JAK inhibitors.
Gerds gave a presentation on this study (
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel 4-Biomarker Panel Improves Early Detection of Pancreatic Cancer
2
Bria-IMT Continues to Improve Survival in Metastatic Breast Cancer
3
Heavy, Consistent Alcohol Intake Increases Risk of Colorectal Cancer
4
FDA Type B Meeting Elucidates Testosterone-Associated Breast Cancer Risks
5



































